Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

被引：0

作者：

Li, Dangran ^{[1
,2
]}

Weng, Shiting ^{[1
,3
]}

Zeng, Kai ^{[1
]}

Xu, Hanmiao ^{[1
]}

Wang, Wenyueyang ^{[1
]}

Shi, Jinsong ^{[1
]}

Chen, Jinghua ^{[1
]}

Chen, Chen ^{[1
]}

机构：

[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Peoples R China

[2] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210029, Peoples R China

[3] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China

来源：

GENE | 2024年 / 895卷

关键词：

LncRNA; MicroRNA; Pancreatic ductal adenocarcinoma; Chemoresistance; Targeted therapy; Tyrosine kinase; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE RESISTANCE; C-MET; FACTOR RECEPTOR; EXPRESSION; PROMOTES; OVEREXPRESSION; SURVIVAL; CHEMORESISTANCE; PROGRESSION;

D O I：

10.1016/j.gene.2023.148007

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Pancreatic cancer (PC) is one of the most malignant tumors with a dismal survival rate, this is primarily due to inevitable chemoresistance. Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) affect the drug resistance and prognosis of PC. Here, we summarize the mechanisms by which TKs or lncRNAs mediate drug resistance and other malignant phenotypes. We also discuss that lncRNAs play oncogenic or tumor suppressor roles and different mechanisms including lncRNA-proteins/microRNAs to mediate drug resistance. Furthermore, we highlight that lncRNAs serve as upstream regulators of TKs mediating drug resistance. Finally, we display the clinical significance of TKs (AXL, EGFR, IGF1R, and MET), clinical trials, and lncRNAs (LINC00460, PVT1, HIF1A-AS1). In the future, TKs and lncRNAs may become diagnostic and prognostic biomarkers or drug targets to overcome the drug resistance of PC.

引用

页数：11

共 50 条

[31] Exosomal long non-coding RNAs in the diagnosis and oncogenesis of pancreatic cancer
Robless, Eunice Eugenia
Howard, Justin Andrew
Casari, Ilaria
Falasca, Marco
CANCER LETTERS, 2021, 501 : 55 - 65
[32] Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs
Lulli, Matteo
Napoli, Cristina
Landini, Ida
Mini, Enrico
Lapucci, Andrea
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
[33] Long Non-Coding RNAs Associated with Mitogen-Activated Protein Kinase in Human Pancreatic Cancer
Ishikawa, Tomohiko
Fukushige, Shinichi
Saiki, Yuriko
Hirose, Katsuya
Hiyoshi, Takako
Ogawa, Takenori
Katori, Yukio
Furukawa, Toru
CANCERS, 2023, 15 (01)
[34] The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer
Lan, Hua
Yuan, Jing
Zeng, Da
Liu, Chu
Guo, Xiaohui
Yong, Jiahui
Zeng, Xiangyang
Xiao, Songshu
FRONTIERS IN GENETICS, 2021, 12
[35] Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Wang, Hongquan
Fleishman, Joshua S.
Cheng, Sihang
Wang, Weixue
Wu, Fan
Wang, Yumin
Wang, Yu
MOLECULAR CANCER, 2024, 23 (01)
[36] The Role of Exosomal Non-Coding RNAs in Colorectal Cancer Drug Resistance
Lampropoulou, Dimitra Ioanna
Pliakou, Evangelia
Aravantinos, Gerasimos
Filippou, Dimitrios
Gazouli, Maria
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[37] Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer
Zhang, Hai-Bo
Hu, Yang
Deng, Jun-Li
Fang, Guo-Ying
Zeng, Ying
FRONTIERS IN PHARMACOLOGY, 2023, 14
[38] Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer
Abildgaard, Cecilie
Do Canto, Luisa M.
Steffensen, Karina D.
Rogatto, Silvia R.
FRONTIERS IN ONCOLOGY, 2020, 9
[39] Long non-coding RNAs and prostate cancer
Misawa, Aya
Takayama, Ken-ichi
Inoue, Satoshi
CANCER SCIENCE, 2017, 108 (11) : 2107 - 2114
[40] Long non-coding RNAs in cancer metabolism
Xiao, Zhen-Dong
Zhuang, Li
Gan, Boyi
BIOESSAYS, 2016, 38 (10) : 991 - 996

← 1 2 3 4 5 →